Washington Growth Strategies LLC Acquires Shares of 842 Thermo Fisher Scientific Inc. $TMO

Washington Growth Strategies LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 842 shares of the medical research company’s stock, valued at approximately $422,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. J. Stern & Co. LLP boosted its holdings in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares during the period. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $15,501,867,000. State Street Corp lifted its holdings in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Corient Private Wealth LP bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $382,547,000. Finally, Capital World Investors grew its holdings in Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TMO shares. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target on the stock. Piper Sandler lifted their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. CLSA started coverage on shares of Thermo Fisher Scientific in a research report on Thursday. They set an “outperform” rating and a C$748.00 target price on the stock. Finally, Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Down 0.9%

TMO stock opened at $612.75 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $647.00. The business has a 50-day simple moving average of $570.91 and a 200 day simple moving average of $515.10. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market cap of $226.56 billion, a PE ratio of 32.96, a price-to-earnings-growth ratio of 2.59 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the firm earned $4.28 EPS. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insiders Place Their Bets

In other news, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 275 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.